Current Hypertension Reports

, Volume 1, Issue 5, pp 394–401 | Cite as

Spectrum of use for the angiotensin-receptor blocking drugs

  • Maurice E. Fabiani
  • Colin I. Johnston
Article

Abstract

The renin-angiotensin system (RAS) plays an important role in regulating blood pressure, and maintaining fluid and electrolyte balance. Angiotensin II is the principal mediator of the RAS and has been implicated in the development of hypertension as well as other forms of cardiovascular and renal disease. Angiotensin II-receptor antagonists are a new class of drugs that inhibit the RAS by selectively blocking the AT1 receptor. These compounds therefore provide more specific and thorough blockade of the RAS by inhibiting the deleterious actions of angiotensin II at the receptor level, irrespective of how this peptide is formed. The increased specificity of action of angiotensin II-receptor antagonists may also circumvent unwanted side-effects normally associated with angiotensin-converting enzyme (ACE) inhibitors (eg, cough and angioedema) as these agents do not interfere with the metabolism of other peptides (eg, bradykinin, substance P, etc.). There is still some concern with angiotensin II-receptor antagonists and the long-term effects of hyper-stimulation of the unopposed AT2 receptor that is caused by elevated levels of angiotensin II. However, it appears that stimulation of the AT2 receptor may actually contribute to the beneficial effects of angiotensin II-receptor antagonists by counteracting the effects mediated by the AT1 receptor. Angiotensin II-receptor antagonists display great therapeutic promise in the field of cardiovascular medicine and are currently being exploited as new antihypertensive agents. These drugs have demonstrated safety, efficacy, and tolerability; however, morbidity and mortality data are still lacking. Nonetheless, it is likely that angiotensin II-receptor antagonists will become part of the medical arsenal against cardiovascular and renal disease, thus consideration should be given to their future use as first-line antihypertensive agents.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Johnston CI: Franz Volhard lecture: renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. J Hypertens 1992, 10(suppl7):S13-S26.Google Scholar
  2. 2.
    Dzau VJ: Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 1988, 77(pt 2):I4-I13.PubMedGoogle Scholar
  3. 3.
    Urata H, Nishimura H, Ganten D: Mechanisms of angiotensin II formation in humans. Eur Heart J 1995, 16(suppl N):79–85.PubMedGoogle Scholar
  4. 4.
    Urata H, Nishimura H, Ganten D, Arakawa K: Angiotensinconverting enzyme-independent pathways of angiotensin II formation in human tissues and cardiovascular diseases. Blood Press 1996, 2(suppl):22–28.Google Scholar
  5. 5.
    Griendling KK, Lassegue B, Alexander RW: Angiotensin receptors and their therapeutic implications. Ann Rev Pharmacol Toxicol 1996, 36:281–306.CrossRefGoogle Scholar
  6. 6.
    Ardaillou R: Angiotensin II receptors. J Am Soc Nephrol 1999, 10(suppl 11):S30-S39.PubMedGoogle Scholar
  7. 7.
    Timmermans PB, Wong PC, Chiu AT, et al.: Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993, 45:205–251.PubMedGoogle Scholar
  8. 8.
    Iwai N, Inagami T: Identification of two subtypes in the rat type I angiotensin II receptor. FEBS Lett 1992, 298:257–260.PubMedCrossRefGoogle Scholar
  9. 9.
    Yoshida H, Kakuchi J, Guo DF, et al.: Analysis of the evolution of angiotensin II type 1 receptor gene in mammals (mouse, rat, bovine and human). Biochem Biophys Res Commun 1992, 186:1042–1049.PubMedCrossRefGoogle Scholar
  10. 10.
    Furuta H, Guo DF, Inagami T: Molecular cloning and sequencing of the gene encoding human angiotensin II type 1 receptor. Biochem Biophys Res Commun 1992, 183:8–13.PubMedCrossRefGoogle Scholar
  11. 11.
    Takayanagi R, Ohnaka K, Sakai Y, et al.: Molecular cloning, sequence analysis and expression of a cDNA encoding human type-1 angiotensin II receptor. Biochem Biophys Res Commun 1992, 183:910–916.PubMedCrossRefGoogle Scholar
  12. 12.
    Bergsma DJ, Ellis C, Kumar C, et al.: Cloning and characterization of a human angiotensin II type 1 receptor. Biochem Biophys Res Commun 1992, 183:989–995.PubMedCrossRefGoogle Scholar
  13. 13.
    Szpirer C, Riviere M, Szpirer J, et al.: Chromosomal assignment of human and rat hypertension candidate genes: type 1 angiotensin II receptor genes and the SA gene. J Hypertens 1993, 11:919–925.PubMedCrossRefGoogle Scholar
  14. 14.
    Lewis JL, Serikawa T, Warnock DG: Chromosomal localization of angiotensin II type 1 receptor isoforms in the rat. Biochem Biophys Res Commun 1993, 194:677–682.PubMedCrossRefGoogle Scholar
  15. 15.
    Tissir F, Riviere M, Guo DF, et al.: Localization of the genes encoding the three rat angiotensin II receptors, Agtr1a, Agtr1b, Agtr2, and the human AGTR2 receptor respectively to rat chromosomes 17q12, 2q24 and Xq34, and the human Xq22. Cytogenet Cell Genet 1995, 71:77–80.PubMedGoogle Scholar
  16. 16.
    Murphy TJ, Takeuchi K, Alexander RW: Molecular cloning of AT1 angiotensin receptors. Am J Hypertens 1992, 5(pt 2):236S-242S.PubMedGoogle Scholar
  17. 17.
    Martin MM, Su B, Elton TS: Molecular cloning of the human angiotensin II type 2 receptor cDNA. Biochem Biophys Res Commun 1994, 205:645–651.PubMedCrossRefGoogle Scholar
  18. 18.
    Martin MM, Su B, Elton TS: Molecular cloning of the human AT2 receptor. Adv Exp Med Biol 1996, 396:153–165.PubMedGoogle Scholar
  19. 19.
    Koike G, Horiuchi M, Yamada T, et al.: Human type 2 angiotensin II receptor gene: cloned, mapped to the X chromosome, and its mRNA is expressed in the human lung. Biochem Biophys Res Commun 1994, 203:1842–1850.PubMedCrossRefGoogle Scholar
  20. 20.
    Mukoyama M, Nakajima M, Horiuchi M, et al.: Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 1993, 268:24539–24542.PubMedGoogle Scholar
  21. 21.
    Chung O, Kuhl H, Stoll M, Unger T: Physiological and pharmacological implications of AT1 versus AT2 receptors. Kidney Int 1998, 67(suppl):S95-S99.CrossRefGoogle Scholar
  22. 22.
    Csikos T, Chung O, Unger T: Receptors and their classification: focus on angiotensin II and the AT2 receptor. J Hum Hypertens 1998, 12:311–318.PubMedCrossRefGoogle Scholar
  23. 23.
    Johnston CI: Angiotensin receptor antagonists: focus on losartan. Lancet 1995, 346:1403–1407.PubMedCrossRefGoogle Scholar
  24. 24.
    Burnier M, Brunner HR: Angiotensin II receptor antagonists in hypertension. Kidney Int 1998, 68(suppl):S107-S111. A recent review on angiotensin II receptor antagonists and their use in the treatment of hypertension.CrossRefGoogle Scholar
  25. 25.
    Minghelli G, Seydoux C, Goy JJ, Burnier M: Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation 1998, 66:268–271.PubMedCrossRefGoogle Scholar
  26. 26.
    Semple PF: Putative mechanisms of cough after treatment with angiotensin-converting enzyme inhibitors. J Hypertens 1995, 13(suppl):S17-S21.CrossRefGoogle Scholar
  27. 27.
    Overlack A: ACE inhibitor-induced cough and bronchospasm: incidence, mechanisms and management. Drug Saf 1996, 15:72–78.PubMedGoogle Scholar
  28. 28.
    Pylypchuk GB: ACE inhibitor-versus angiotensin II blockerinduced cough and angioedema. Ann Pharmacother 1998, 32:1060–1066.PubMedCrossRefGoogle Scholar
  29. 29.
    Voors AA, Pinto YM, Buikema H, et al.: Dual pathway for angiotensin II formation in human internal mammary arteries. Br J Pharmacol 1998, 125:1028–1032.PubMedCrossRefGoogle Scholar
  30. 30.
    Johnston CI, Naitoh M, Burrell LM: Rationale and pharmacology of angiotensin II receptor antagonists: current status and future issues. J Hypertens 1997, 15(suppl):S3-S6. A review outlining the pharmacology of angiotensin II receptor antagonists and the rationale for their use as antihypertensive agents.CrossRefGoogle Scholar
  31. 31.
    Johnston CI, Risvanis J: Preclinical pharmacology of angiotensin II receptor antagonists: update and outstanding issues. Am J Hypertens 1997, 10(pt 2):306S-310S.PubMedCrossRefGoogle Scholar
  32. 32.
    McIntyre M, Caffe SE, Michalak RA, Reid JL: Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension. Pharmacol Ther 1997, 74:181–194.PubMedCrossRefGoogle Scholar
  33. 33.
    Markham A, Goa KL: Valsartan: a review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997, 54:299–311.PubMedGoogle Scholar
  34. 34.
    Brown MJ: Irbesartan treatment in hypertension. Hosp Med 1998, 59:808–811.PubMedGoogle Scholar
  35. 35.
    McClellan KJ, Goa KL: Candesartan cilexetil: a review of its use in essential hypertension. Drugs 1998, 56:847–869.PubMedCrossRefGoogle Scholar
  36. 36.
    Tikkanen I, Omvik P, Jensen HA: Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens 1995, 13:1343–1351.PubMedCrossRefGoogle Scholar
  37. 37.
    Townsend R, Haggert B, Liss C, Edelman JM: Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Clin Ther 1995, 17:911–923.PubMedCrossRefGoogle Scholar
  38. 38.
    Oparil S, Barr E, Elkins M, et al.: Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. Clin Ther 1996, 18:608–625.PubMedCrossRefGoogle Scholar
  39. 39.
    Weir MR, Elkins M, Liss C, et al.: Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. Clin Ther 1996, 18:411–428.PubMedCrossRefGoogle Scholar
  40. 40.
    Conlin PR, Elkins M, Liss C, et al.: A study of losartan, alone or with hydrochlorothiazide vs nifedipine GITS in elderly patients with diastolic hypertension. J Hum Hypertens 1998, 12:693–699.PubMedCrossRefGoogle Scholar
  41. 41.
    Chan JC, Critchley JA, Lappe JT, et al.: Randomised, doubleblind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension. J Hum Hypertens 1995, 9:765–771.PubMedGoogle Scholar
  42. 42.
    Dahlof B, Keller SE, Makris L, et al.: Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens 1995, 8:578–583.PubMedCrossRefGoogle Scholar
  43. 43.
    Roca-Cusachs A, Oigman W, Lepe L, et al.: A randomized, double-blind comparison of the antihypertensive efficacy and safety of once-daily losartan compared to twice-daily captopril in mild to moderate essential hypertension. Acta Cardiol 1997, 52:495–506.PubMedGoogle Scholar
  44. 44.
    Kassler-Taub K, Littlejohn T, Elliott W, et al.: Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators. Am J Hypertens 1998, 11(part 1):445–453.PubMedCrossRefGoogle Scholar
  45. 45.
    Oparil S, Guthrie R, Lewin AJ, et al.: An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators. Clin Ther 1998, 20:398–409.PubMedCrossRefGoogle Scholar
  46. 46.
    Andersson OK, Neldam S: The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 1998, 7:53–59.PubMedCrossRefGoogle Scholar
  47. 47.
    MacKay JH, Arcuri KE, Goldberg AI, et al.: Losartan and lowdose hydrochlorothiazide in patients with essential hypertension: a double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 1996, 156:278–285.PubMedCrossRefGoogle Scholar
  48. 48.
    Ruilope LM, Simpson RL, Toh J, et al.: Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients. Blood Press 1996, 5:32–40.PubMedGoogle Scholar
  49. 49.
    Gigante B, Piras O, De Paolis P, et al.: Role of the angiotensin II AT2-subtype receptors in the blood pressure-lowering effect of losartan in salt-restricted rats. J Hypertens 1998, 16(part 2):2039–2043. This study shows that in the salt-restricted rat blockade of AT2 receptors with PD123319 increases blood pressure and offsets the blood pressure lowering effect of losartan.PubMedCrossRefGoogle Scholar
  50. 50.
    Dahlof B, Devereux R, de Faire U, et al.: The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens 1997, 10(part 1):705–713.PubMedCrossRefGoogle Scholar
  51. 51.
    Mann J, Julius S: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension: rationale and design. Blood Press 1998, 7:176–183.PubMedCrossRefGoogle Scholar
  52. 52.
    Schrader J, Rothemeyer M, Luders S, Kollmann K: Hypertension and stroke: rationale behind the ACCESS trial. Acute Candesartan Cilexetil Evaluation in Stroke Survivors. Basic Res Cardiol 1998, 93(suppl 2):69–78.PubMedCrossRefGoogle Scholar
  53. 53.
    Crozier I, Ikram H, Awan N, et al.: Losartan in heart failure: hemodynamic effects and tolerability. Losartan Hemodynamic Study Group. Circulation 1995, 91:691–697.PubMedGoogle Scholar
  54. 54.
    Mazayev VP, Fomina IG, Kazakov EN, et al.: Valsartan in heart failure patients previously untreated with an ACE inhibitor. Int J Cardiol 1998, 65:239–246.PubMedCrossRefGoogle Scholar
  55. 55.
    Lang RM, Elkayam U, Yellen LG, et al.: Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators. J Am Coll Cardiol 1997, 30:983–991.PubMedCrossRefGoogle Scholar
  56. 56.
    Hamroff G, Blaufarb I, Mancini D, et al.: Angiotensin II-receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure. J Cardiovasc Pharmacol 1997, 30:533–536.PubMedCrossRefGoogle Scholar
  57. 57.
    Pitt B, Segal R, Martinez FA, et al.: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997, 349:747–752. This paper reports an apparent greater reduction in mortality in elderly patients with congestive heart failure receiving losartan compared to captopril.PubMedCrossRefGoogle Scholar
  58. 58.
    Tsuyuki RT, Yusuf S, Rouleau JL, et al.: Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Cardiol 1997, 13:1166–1174.PubMedGoogle Scholar
  59. 59.
    Yusuf S, Maggioni AP, Held P, Rouleau JL: Effects of candesartan, enalapril, or their combination on exercise capacity, ventricular function, clinical deterioration and quality of life in heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study [abstract]. Circulation 1997, 96:2527.Google Scholar
  60. 60.
    Yusuf S: Phase I results of the Randomized Evaluation of Left Ventricular Dysfunction (RESOLVD) trial. Am J Managed Care 1998, 4(suppl S):S380-S383. A pilot heart failure study that was stopped prematurely due to an apparent (non-significant) increase in mortality in patients receiving candesartan cilexetil alone or in combination with enalapril compared to enalapril alone.Google Scholar
  61. 61.
    Dahlof B: Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy. Blood Press 1994 2(suppl):35–40.Google Scholar
  62. 62.
    Schmieder RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA 1996, 275:1507–1513.PubMedCrossRefGoogle Scholar
  63. 63.
    Schmieder RE, Schlaich MP, Klingbeil AU, Martus P: Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 1998, 13:564–569.PubMedCrossRefGoogle Scholar
  64. 64.
    Tedesco MA, Ratti G, Aquino D, et al.: Effects of losartan on hypertension and left ventricular mass: a long-term study. J Hum Hypertens 1998, 12:505–510.PubMedCrossRefGoogle Scholar
  65. 65.
    Thurmann PA, Kenedi P, Schmidt A, et al.: Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998, 98:2037–2042.PubMedGoogle Scholar
  66. 66.
    Kahan T: The importance of left ventricular hypertrophy in human hypertension. J Hypertens 1998, 16(suppl 7):S23-S29.Google Scholar
  67. 67.
    Kahan T, Malmqvist K, Edner M, et al.: Rate and extent of left ventricular hypertrophy regression: a comparison of angiotensin II blockade with irbesrtan and beta-blockade [abstract]. J Am Coll Cardiol 1998, 31:212.CrossRefGoogle Scholar
  68. 68.
    Cohen A, Bregman B, Agabiti Rosei E, et al.: Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left VEntricular hypertrophy Regression. J Hum Hypertens 1998, 12:479–483.PubMedCrossRefGoogle Scholar
  69. 69.
    Dahlof B, Devereux RB, Julius S, et al.: Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Hypertension 1998, 32:989–997.PubMedGoogle Scholar
  70. 70.
    Wolf G: Angiotensin II: a pivotal factor in the progression of renal diseases. Nephrol Dial Transplant 1999, 14 (suppl 1):42–44.PubMedCrossRefGoogle Scholar
  71. 71.
    Maschio G, Alberti D, Janin G, et al.: Effect of the angiotensinconverting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996, 334:939–945.PubMedCrossRefGoogle Scholar
  72. 72.
    Antonios TF, MacGregor GA: Angiotensin converting enzyme inhibitors in hypertension: potential problems. J Hypertens 1995, 13(suppl 3):S11-S16.CrossRefGoogle Scholar
  73. 73.
    Nielsen S, Dollerup J, Nielsen B, et al.: Losartan reduces albuminuria in patients with essential hypertension: an enalapril controlled 3 months study. Nephrol Dial Transplant 1997, 12(suppl 2):19–23.PubMedGoogle Scholar
  74. 74.
    Fernandez-Andrade C, Russo D, Iversen B, et al.: Comparison of losartan and amlodipine in renally impaired hypertensive patients. Kidney Int 1998, 68(suppl):S120-S124.Google Scholar
  75. 75.
    Buter H, Navis G, de Zeeuw D, de Jong PE: Renal hemodynamic effects of candesartan in normal and impaired renal function in humans. Kidney Int 1997, 63(suppl):S185–187.Google Scholar
  76. 76.
    Plum J, Bunten B, Nemeth R, Grabensee B: Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. J Am Soc Nephrol 1998, 9:2223–2234.PubMedGoogle Scholar
  77. 77.
    Goldberg AI, Dunlay MC, Sweet CS: Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995, 75:793–795.PubMedCrossRefGoogle Scholar
  78. 78.
    Belcher G, Hubner R, George M, et al.: Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension. J Hum Hypertens 1997, 11(suppl 2):S85-S89.PubMedGoogle Scholar
  79. 79.
    Simon TA, Gelarden RT, Freitag SA, et al.: Safety of irbesartan in the treatment of mild to moderate systemic hypertension. Am J Cardiol 1998, 82:179–182.PubMedCrossRefGoogle Scholar
  80. 80.
    Paster RZ, Snavely DB, Sweet AR, et al.: Use of losartan in the treatment of hypertensive patients with a history of cough induced by angiotensin-converting enzyme inhibitors. Clin Ther 1998, 20:978–989.PubMedCrossRefGoogle Scholar
  81. 81.
    van Rijnsoever EW, Kwee-Zuiderwijk WJ, Feenstra J: Angioneurotic edema attributed to the use of losartan. Arch Intern Med 1998, 158:2063–2065. A review of some case reports of angioedema associated with the use of losartan.PubMedCrossRefGoogle Scholar
  82. 82.
    Frye CB, Pettigrew TJ: Angioedema and photosensitive rash induced by valsartan. Pharmacotherapy 1998, 18:866–868.PubMedGoogle Scholar
  83. 83.
    Sharma PK, Yium JJ: Angioedema associated with angiotensin II receptor antagonist losartan. South Med J 1997, 90:552–553.PubMedGoogle Scholar
  84. 84.
    Acker CG, Greenberg A: Angioedema induced by the angiotensin II blocker losartan. N Engl J Med 1995, 333:1572.PubMedCrossRefGoogle Scholar
  85. 85.
    Mastrobattista JM: Angiotensin converting enzyme inhibitors in pregnancy. Semin Perinatol 1997, 21:124–134.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science, Inc 1999

Authors and Affiliations

  • Maurice E. Fabiani
    • 1
  • Colin I. Johnston
    • 1
  1. 1.Department of MedicineUniversity of Melbourne, Austin and Repatriation Medical CentreHeidelbergAustralia

Personalised recommendations